Nintedanib

Drug Profile

Nintedanib

Alternative Names: BIBF-1120; Intedanib; Ofev; Vargatef

Latest Information Update: 13 Feb 2017

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Acetamides; Antineoplastics; Esters; Indoles; Piperazines; Small molecules
  • Mechanism of Action Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Interstitial lung diseases; Systemic scleroderma; Idiopathic pulmonary fibrosis; Mesothelioma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Idiopathic pulmonary fibrosis; Non-small cell lung cancer
  • Phase III Colorectal cancer; Interstitial lung diseases; Mesothelioma; Ovarian cancer; Systemic scleroderma
  • Phase II Bladder cancer; Endometrial cancer; Hepatocellular carcinoma; Renal cell carcinoma
  • Phase I Fallopian tube cancer; Peritoneal cancer; Solid tumours
  • No development reported Multiple myeloma
  • Discontinued Prostate cancer

Most Recent Events

  • 01 Jan 2017 Phase-III clinical trials in Interstitial lung diseases in Canada, USA (PO) (NCT02999178)
  • 01 Jan 2017 Launched for Non-small cell lung cancer (Late-stage disease, Combination therapy, Second-line therapy or greater) in India (PO) (Launched before January 2017)
  • 19 Dec 2016 Boehringer Ingelheim plans a phase III trial for Interstitial lung diseases in Argentina, Belgium, Canada, Chile, China, France, Germany, Italy, Japan, Poland, Russia, Spain, South Korea, USA and United Kingdom (PO) (NCT02999178)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top